CN1129428C - 内皮素受体拮抗剂 - Google Patents
内皮素受体拮抗剂 Download PDFInfo
- Publication number
- CN1129428C CN1129428C CN94192388A CN94192388A CN1129428C CN 1129428 C CN1129428 C CN 1129428C CN 94192388 A CN94192388 A CN 94192388A CN 94192388 A CN94192388 A CN 94192388A CN 1129428 C CN1129428 C CN 1129428C
- Authority
- CN
- China
- Prior art keywords
- hydrogen
- alkyl
- formula
- compound
- indan
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C62/00—Compounds having carboxyl groups bound to carbon atoms of rings other than six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C62/30—Unsaturated compounds
- C07C62/34—Unsaturated compounds containing ether groups, groups, groups, or groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
- C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
- C07C69/734—Ethers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
- C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
- C07C69/738—Esters of keto-carboxylic acids or aldehydo-carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
- C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
- C07D317/60—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
- C07F9/65515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring
- C07F9/65517—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring condensed with carbocyclic rings or carbocyclic ring systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Steroid Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US6681893A | 1993-04-27 | 1993-04-27 | |
| US08/066,818 | 1993-04-27 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1124923A CN1124923A (zh) | 1996-06-19 |
| CN1129428C true CN1129428C (zh) | 2003-12-03 |
Family
ID=22071916
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN94192388A Expired - Fee Related CN1129428C (zh) | 1993-04-27 | 1994-04-26 | 内皮素受体拮抗剂 |
Country Status (28)
| Country | Link |
|---|---|
| EP (1) | EP0699069B9 (https=) |
| JP (1) | JP3346571B2 (https=) |
| KR (1) | KR100331667B1 (https=) |
| CN (1) | CN1129428C (https=) |
| AP (1) | AP573A (https=) |
| AT (1) | ATE213156T1 (https=) |
| AU (1) | AU682038B2 (https=) |
| BR (1) | BR9406572A (https=) |
| CA (1) | CA2160914A1 (https=) |
| CZ (1) | CZ291189B6 (https=) |
| DE (1) | DE69429861T2 (https=) |
| DK (1) | DK0699069T3 (https=) |
| DZ (1) | DZ1773A1 (https=) |
| ES (1) | ES2172535T3 (https=) |
| FI (1) | FI955103A7 (https=) |
| HU (2) | HUT73763A (https=) |
| IL (1) | IL109443A0 (https=) |
| MA (1) | MA23172A1 (https=) |
| NO (1) | NO313754B1 (https=) |
| NZ (1) | NZ266314A (https=) |
| PL (1) | PL175392B1 (https=) |
| PT (1) | PT699069E (https=) |
| RU (1) | RU2130920C1 (https=) |
| SG (1) | SG49667A1 (https=) |
| SI (1) | SI9400195B (https=) |
| SK (1) | SK130595A3 (https=) |
| TW (1) | TW330204B (https=) |
| WO (1) | WO1994025013A1 (https=) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH10510510A (ja) * | 1994-06-09 | 1998-10-13 | スミスクライン・ビーチャム・コーポレイション | エンドセリン受容体拮抗物質 |
| JPH10501812A (ja) * | 1994-06-20 | 1998-02-17 | スミスクライン・ビーチャム・コーポレイション | エンドセリン受容体拮抗薬 |
| JPH10512855A (ja) * | 1994-12-23 | 1998-12-08 | スミスクライン・ビーチャム・コーポレイション | 化合物および方法 |
| US6162932A (en) * | 1995-11-08 | 2000-12-19 | Smithkline Beecham Corporation | Stereoselective synthesis of endothelin receptor antagonists |
| ZA969363B (en) * | 1995-11-08 | 1997-11-18 | Smithkline Beecham Corp | An improved process for preparing aromatic ring-fused cyclopentane derivatives. |
| US6080862A (en) * | 1995-11-08 | 2000-06-27 | Smithkline Beecham Corporation | Stereoselective synthesis of endothelin receptor antagonists |
| CA2236924A1 (en) * | 1995-11-08 | 1997-05-15 | Smithkline Beecham Corporation | Stereoselective synthesis of endothelin receptor antagonists |
| US5977117A (en) * | 1996-01-05 | 1999-11-02 | Texas Biotechnology Corporation | Substituted phenyl compounds and derivatives thereof that modulate the activity of endothelin |
| AU723351B2 (en) | 1996-04-04 | 2000-08-24 | Msd K.K. | Method of treating heart failure with endothelin antagonists |
| US5932553A (en) | 1996-07-18 | 1999-08-03 | The Regents Of The University Of California | Illudin analogs useful as antitumor agents |
| US5723632A (en) | 1996-08-08 | 1998-03-03 | Mgi Pharma, Inc. | Total synthesis of antitumor acylfulvenes |
| EP0924207A4 (en) | 1996-08-27 | 2001-06-13 | Shionogi & Co | CHROMENE-3-CARBOXYLATE DERIVATIVES |
| US5929106A (en) * | 1997-10-27 | 1999-07-27 | Smithkline Beecham Corporation | Endothelin receptor antagonists |
| US6025328A (en) | 1998-02-20 | 2000-02-15 | The Regents Of The University Of California | Antitumor agents |
| US7141603B2 (en) | 1999-02-19 | 2006-11-28 | The Regents Of The University California | Antitumor agents |
| US6410554B1 (en) | 1998-03-23 | 2002-06-25 | Merck & Co., Inc. | Combination therapy for the treatment of benign prostatic hyperplasia |
| CA2327928A1 (en) * | 1998-04-09 | 1999-10-21 | Merck & Co., Inc. | Phosphate-mediated cyclization |
| TWI274750B (en) | 1999-01-12 | 2007-03-01 | Abbott Gmbh & Co Kg | Triazole compounds showing high affinity to dopamine D3 receptor and pharmaceutical composition comprising the same |
| US8168616B1 (en) | 2000-11-17 | 2012-05-01 | Novartis Ag | Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension |
| GB0327839D0 (en) | 2003-12-01 | 2003-12-31 | Novartis Ag | Organic compounds |
| NZ549535A (en) | 2004-03-17 | 2010-11-26 | Novartis Ag | Use of aliskiren for treating renal and other disorders |
| US7423176B2 (en) | 2004-04-13 | 2008-09-09 | Cephalon, Inc. | Bicyclic aromatic sulfinyl derivatives |
| MX2007007482A (es) | 2004-12-21 | 2007-07-20 | Hoffmann La Roche | Derivados de tetralina e indano y usos de los mismos como antagonistas de 5-ht. |
| US20100040666A1 (en) * | 2005-06-24 | 2010-02-18 | Hiroshi Azuma | Method for Control of Drug Elution Rate and Composition for Coating of Drug-Eluting Stent |
| WO2007019308A2 (en) | 2005-08-03 | 2007-02-15 | The Regents Of The University Of California | Illudin analogs useful as anticancer agents |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3737455A (en) * | 1971-01-21 | 1973-06-05 | Merck & Co Inc | Substituted 1-(loweralkyl-sulfinylbenzylidene)-3-indenyloxyacetic acid and esters thereof |
| UA44686C2 (uk) * | 1991-11-05 | 2002-03-15 | Смітклайн Бічем Корпорейшн | Похідні індану або індену як антагоністи ендотелінових рецепторів, фармацевтична композиція на їх основі, спосіб їх одержання та спосіб пригнічення ендотелінових рецепторів |
-
1994
- 1994-04-26 DZ DZ940038A patent/DZ1773A1/fr active
- 1994-04-26 DK DK94915903T patent/DK0699069T3/da active
- 1994-04-26 JP JP52449694A patent/JP3346571B2/ja not_active Expired - Fee Related
- 1994-04-26 BR BR9406572A patent/BR9406572A/pt not_active Application Discontinuation
- 1994-04-26 AU AU67750/94A patent/AU682038B2/en not_active Ceased
- 1994-04-26 DE DE69429861T patent/DE69429861T2/de not_active Expired - Fee Related
- 1994-04-26 WO PCT/US1994/004603 patent/WO1994025013A1/en not_active Ceased
- 1994-04-26 RU RU95122388A patent/RU2130920C1/ru active
- 1994-04-26 ES ES94915903T patent/ES2172535T3/es not_active Expired - Lifetime
- 1994-04-26 SI SI9400195A patent/SI9400195B/sl not_active IP Right Cessation
- 1994-04-26 CZ CZ19952835A patent/CZ291189B6/cs not_active IP Right Cessation
- 1994-04-26 PT PT94915903T patent/PT699069E/pt unknown
- 1994-04-26 IL IL10944394A patent/IL109443A0/xx unknown
- 1994-04-26 MA MA23478A patent/MA23172A1/fr unknown
- 1994-04-26 SK SK1305-95A patent/SK130595A3/sk unknown
- 1994-04-26 NZ NZ266314A patent/NZ266314A/xx not_active IP Right Cessation
- 1994-04-26 HU HU9501931A patent/HUT73763A/hu unknown
- 1994-04-26 FI FI955103A patent/FI955103A7/fi not_active Application Discontinuation
- 1994-04-26 EP EP94915903A patent/EP0699069B9/en not_active Expired - Lifetime
- 1994-04-26 AT AT94915903T patent/ATE213156T1/de not_active IP Right Cessation
- 1994-04-26 PL PL94311272A patent/PL175392B1/pl unknown
- 1994-04-26 CN CN94192388A patent/CN1129428C/zh not_active Expired - Fee Related
- 1994-04-26 HU HU9503067A patent/HU9503067D0/hu unknown
- 1994-04-26 CA CA002160914A patent/CA2160914A1/en not_active Abandoned
- 1994-04-26 KR KR1019950704682A patent/KR100331667B1/ko not_active Expired - Fee Related
- 1994-04-26 AP APAP/P/1994/000636A patent/AP573A/en active
- 1994-04-26 SG SG1996003492A patent/SG49667A1/en unknown
- 1994-07-01 TW TW083106015A patent/TW330204B/zh not_active IP Right Cessation
-
1995
- 1995-10-26 NO NO19954291A patent/NO313754B1/no unknown
Non-Patent Citations (1)
| Title |
|---|
| THECHEMICALSOCIETYOFJAPANVOL.59NOL.11 1986-11-01 KIMIAKI,YAMAMURA,FORMATION,OF,2-SUBSTITUED,1,3-DIPHENYLINDENES,BY,AN,N-BROMOSUCCINIMIDE,PROMPTED,DEH * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1129428C (zh) | 内皮素受体拮抗剂 | |
| CN1034569C (zh) | Et(endothelin)受体拮抗物 | |
| CN1088581A (zh) | 内皮素受体拮抗剂 | |
| CN1096513A (zh) | 内皮素受体拮抗剂 | |
| CN1203070C (zh) | 凝血酶受体拮抗药 | |
| CN1289496C (zh) | 新的帕罗西汀盐酸盐无水合物的制备方法 | |
| CN1151130C (zh) | 神经保护的3-(哌啶基-1)-苯并二氢吡喃-4,7-二醇和1-(4-氢化苯基)-2-(哌啶基-1)链烷醇衍生物 | |
| CN1159325A (zh) | 帕金森氏综合症的协同治疗 | |
| CN1173974C (zh) | 作为p物质拮抗剂的哌啶基氨基甲基三氟甲基环醚化合物 | |
| CN1117966A (zh) | 联苯基衍生物 | |
| CN1053607A (zh) | 用于治疗aids的人体免疫缺乏病毒蛋白酶的抑制剂 | |
| CN1049336C (zh) | 异恶唑衍生物在制备治疗肠应激综合征的组合物中的用途 | |
| CN1290258A (zh) | 具有5-羟色胺1a受体活性的芳基哌嗪类化合物 | |
| CN1290265A (zh) | 凝血酶受体拮抗剂 | |
| CN1053923A (zh) | 具有神经保护作用的3-哌啶子基-4-羟基苯并二氯吡喃衍生物 | |
| CN1117965A (zh) | 取代的4-苯基-吡啶酮和4-苯基-2-烷氧基吡啶 | |
| CN1071755C (zh) | 杂环甲酰胺衍生物及其作为治疗剂的用途 | |
| CN1870999A (zh) | 炔烃ⅰ | |
| CN85107496A (zh) | 制备四氢化萘衍生物的方法 | |
| CN1252068C (zh) | 作为伤害感受蛋白受体orl-1优良配体的杂芳基衍生物 | |
| CN1105990A (zh) | 苯基链烷醇胺衍生物 | |
| CN1024663C (zh) | 治疗气喘用的取代的四氢化萘类化合物的制备方法 | |
| CN1228082A (zh) | 双吲哚基马来酰亚胺的合成 | |
| CN1085209C (zh) | 5,11-二氢二苯并[b,e][1,4]氧氮杂䓬衍生物以及含该衍生物的医药组合物 | |
| CN1196680A (zh) | 皮内素受体拮抗剂 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |